Financials
Financial year 2025
RESEARCH, DEVELOPMENT AND SALES FOR MEDECINE from Hasselt, company number BE0453323857, closed financial year 2025 with a result of € 278,261 after tax. For that financial year RESEARCH, DEVELOPMENT AND SALES FOR MEDECINE recorded a gross margin of € 375,984 and equity of € 771,485. Compared with financial year 2024, the result moved from € 199,171 to € 278,261. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 8, 2026.
€ 771,485
▲ 56% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 278,261
▲ 40% vs 2024
Profit after tax over the fiscal year.
€ 597,381
▲ 27% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 561,038.
People and assets in 2025
0
Average over the fiscal year, from the social balance sheet.
€ 3,465
▼ 70% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 19,463
▲ 12% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 35,867
▲ 20% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 245,374 | € 225,701 | € 271,466 | € 375,984 | ▲ 39% |
| Profit after taxes | € 175,074 | € 165,000 | € 199,171 | € 278,261 | ▲ 40% |
| Equity | € 429,053 | € 594,053 | € 493,224 | € 771,485 | ▲ 56% |
| Total debts | € 158,211 | € 77,090 | € 397,264 | € 85,114 | ▼ 79% |
| Cash | € 434,771 | € 137,279 | € 470,136 | € 597,381 | ▲ 27% |
| Retained profit | € 218,606 | € 383,606 | € 282,777 | € 561,038 | ▲ 98% |
| Dividend | € 0 | € 0 | € 300,000 | € 0 | ▼ 100% |
| Bank debt | € 101,408 | € 212 | € 15 | € 0 | ▼ 100% |
| Balance sheet total | € 587,264 | € 671,143 | € 890,488 | € 856,599 | ▼ 4% |
Key figures of RESEARCH, DEVELOPMENT AND SALES FOR MEDECINE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to RESEARCH, DEVELOPMENT AND SALES FOR MEDECINE?
What happened at RESEARCH, DEVELOPMENT AND SALES FOR MEDECINE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Maria Berghs stepped down as director. NBB
- Peter Reyskens stepped down as director. NBB
- Freddy Reyskens stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 278,261 (▲ 40% vs 2024). Source: NBB ↗
- Peter Reyskens became a director. NBB
- Maria Berghs became a director. NBB
- New establishment in Hasselt. KBO
- Freddy Reyskens became a director. NBB
In short
From € 175,074 profit in 2022 to € 278,261 profit in 2025.
Paid € 277,112 in corporate taxes since 2022.
Best year ever: 2025, with € 278,261 profit.
Paid out € 300,000 in dividends to the owners in total.
A new publication or filing at RESEARCH, DEVELOPMENT AND SALES FOR MEDECINE? We notify you, reason included.
Follow RESEARCH, DEVELOPMENT AND SALES FOR MEDECINEDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by RESCOM (100%).
Directors
According to the 2025 annual accounts
Maria Berghs
Director
since 2000 · until 2027
since 2004 · until 2027
Freddy Reyskens
Managing director
since 1994 · until 2027
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Gaarveldstraat 83
3500 Hasselt
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0453.323.857
- VAT number
- BE 0453.323.857
- Registered office
- Gaarveldstraat 83, 3500 Hasselt
- Names & denominations
- RESEARCH, DEVELOPMENT AND SALES FOR MEDECINE · R.D.S.M.
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 29 August 1994
- Peppol
- Active · Active since 2 Dec 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten